Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIIb randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (150 microg o.d.) on exercise endurance in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Next Previous
Search
Trial Profile

A phase IIIb randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (150 microg o.d.) on exercise endurance in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis; Novartis Pharma

    • Most Recent Events

    • 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database. (2009-07-08)
    • 21 Apr 2012 Planned number of patients changed from 83 to 96 as reported by EudraCT.
    • 21 Apr 2012 Additional trial location (Germany) identified as reported by EudraCT.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top